Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) was upgraded by stock analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a research report issued on Thursday, June 22nd.
Other research analysts have also issued research reports about the stock. TheStreet lowered shares of Aeglea BioTherapeutics from a “c-” rating to a “d+” rating in a report on Friday, May 26th. Zacks Investment Research upgraded shares of Aeglea BioTherapeutics from a “hold” rating to a “strong-buy” rating and set a $8.00 price target on the stock in a report on Wednesday, April 12th.
Aeglea BioTherapeutics (NASDAQ:AGLE) opened at 3.60 on Thursday. The firm’s market cap is $48.43 million. The company has a 50 day moving average of $3.73 and a 200-day moving average of $5.43. Aeglea BioTherapeutics has a one year low of $3.28 and a one year high of $10.34.
Aeglea BioTherapeutics (NASDAQ:AGLE) last posted its quarterly earnings results on Tuesday, May 9th. The biotechnology company reported ($0.47) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.47). Aeglea BioTherapeutics had a negative net margin of 492.49% and a negative return on equity of 35.69%. The firm had revenue of $0.98 million for the quarter. On average, equities research analysts predict that Aeglea BioTherapeutics will post ($2.05) earnings per share for the current year.
A number of hedge funds have recently modified their holdings of the stock. Perceptive Advisors LLC purchased a new stake in shares of Aeglea BioTherapeutics during the fourth quarter valued at about $451,000. Norges Bank purchased a new stake in shares of Aeglea BioTherapeutics during the fourth quarter valued at about $275,000. Renaissance Technologies LLC purchased a new stake in shares of Aeglea BioTherapeutics during the first quarter valued at about $270,000. Bank of New York Mellon Corp purchased a new stake in shares of Aeglea BioTherapeutics during the first quarter valued at about $157,000. Finally, Alyeska Investment Group L.P. increased its stake in shares of Aeglea BioTherapeutics by 9.2% in the fourth quarter. Alyeska Investment Group L.P. now owns 119,707 shares of the biotechnology company’s stock valued at $521,000 after buying an additional 10,062 shares during the period. 31.44% of the stock is owned by institutional investors.
About Aeglea BioTherapeutics
Aeglea BioTherapeutics, Inc is a biotechnology company, which is engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism (IEM) and cancer. The Company’s product pipeline includes AEB1102, AEB3103, AEB2109 and AEB4104. Its lead product candidate, AEB1102, is engineered to degrade the amino acid arginine and is being developed to treat over two extremes of arginine metabolism, including arginine excess in patients with Arginase I deficiency, an IEM, as well as some cancers, which have shown to have a metabolic dependence on arginine.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Aeglea BioTherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea BioTherapeutics Inc. and related companies with our FREE daily email newsletter.